Showing 1311-1320 of 10904 results for "".
- 2-Year Icotrokinra Data Show Sustained Clearance in High-Impact Psoriasis Siteshttps://practicaldermatology.com/news/2-year-icotrokinra-data-show-sustained-clearance-in-high-impact-psoriasis-sites/2488612/Johnson & Johnson reported 2-year Phase 3 data showing sustained skin clearance with icotrokinra in adults and adolescents aged 12 years or older with plaque psoriasis involving high-impact sites. The late-breaking ICONIC-TOTAL results were presented at the Europ
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://practicaldermatology.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- Sun Pharma Reports 2-Year Deuruxolitinib Data in Severe Alopecia Areatahttps://practicaldermatology.com/news/sun-pharma-reports-2-year-deuruxolitinib-data-in-severe-alopecia-areata/2488607/Long-term treatment with deuruxolitinib (LEQSELVI, Sun Pharmaceutical Industries Limited) showed sustained scalp hair response through Week 108 among selected responders with severe alopecia areata (AA), according to open-label extension (OLE) data presented at the 2026 European Academy of Dermat
- Delgocitinib Shows Real-World and Adolescent CHE Outcomes: Studyhttps://practicaldermatology.com/news/eadv-2026-delgocitinib-shows-real-world-and-adolescent-che-outcomes/2488596/LEO Pharma presented new delgocitinib cream data at the 35th European Academy of Dermatology and Venereology (EADV) Congress, including interim real-world findings in adults and post hoc phase 3 analyses examining symptoms and quality of life in adolescents with moderate to
- Kenvue Presents New Skin and Hair Research at EADV 2026https://practicaldermatology.com/news/kenvue-presents-new-skin-and-hair-research-at-eadv-2026/2488594/New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 examines topical formulations containing niacinamide, trehalose, colloidal oat, and minoxidil across several skin and hair concerns. Kenvue announced 12 data sets invol
- Three-Year Data Detail Bimekizumab Outcomes in Hidradenitis Suppurativahttps://practicaldermatology.com/news/three-year-data-detail-bimekizumab-outcomes-in-hidradenitis-suppurativa/2488593/New analyses of the Phase 3 BE HEARD clinical program presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 evaluated long-term inflammatory lesions, tunnels, quality of life, and safety with bimekizumab (Bimzelx; UCB) in adults with moderate
- Tulisokibart Meets Phase 2b Primary Endpoint in Hidradenitis Suppurativahttps://practicaldermatology.com/news/tulisokibart-meets-phase-2b-primary-endpoint-in-hidradenitis-suppurativa/2488592/Tulisokibart, an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), met the primary endpoint in a Phase 2b trial evaluating the therapy in patients with moderate-to-severe hidradenitis suppurativa (HS), according to results presente
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://practicaldermatology.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- Simone Biles Shares Seborrheic Dermatitis, Eczema Journey in New Arcutis Campaignhttps://practicaldermatology.com/news/simone-biles-shares-seborrheic-dermatitis-eczema-journey-in-new-arcutis-campaign/2488580/Arcutis has partnered with World Champion gymnast Simone Biles to launch Skin to Believe In, an awareness campaign focused on seborrheic dermatitis and atopic dermatitis, according to a press release from the company. The campaign centers on Biles’ experience managin
- Galderma EADV Data to Explore Nemolizumab, Acne, and Fragile Skinhttps://practicaldermatology.com/news/galderma-eadv-data-to-explore-nemolizumab-acne-and-fragile-skin/2488562/Galderma announced it will be presenting 19 abstracts, including 2 oral presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, with research spanning inflammatory skin diseases, sensitive and fragile skin, skin longevity, and acne. <